ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40430355

Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction.

Fischer F and 2 others. Molecules, 2025. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction. Papers, record 40430355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40430355

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction.
PubMed
Journal
Molecules
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-05-31
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fischer FFlorianhttps://orcid.org/0009-0000-0752-0023
2Temml VVeronikahttps://orcid.org/0000-0001-7662-9882
3Schuster DDanielahttps://orcid.org/0000-0002-9933-8938

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug DiscoveryMajor topic
Janus Kinase InhibitorsMajor topic
Janus KinasesMajor topic
Humans
Pesticides
Molecular Docking Simulation
Models, Molecular
Pharmacophore

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
T942Austrian Science FundPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References273

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117,253,679Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.J Med Chem2007https://conductscience.org/library/papers/17253679PubMed
228,626,517Janus-Associated Kinase 1 (JAK1) Inhibitors as Potential Treatment for Immune Disorders.ACS Med Chem Lett2017https://conductscience.org/library/papers/28626517PubMed
332,352,776Monomeric Targeted Protein Degraders.J Med Chem2020https://conductscience.org/library/papers/32352776PubMed
426,288,682Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors.ACS Med Chem Lett2015https://conductscience.org/library/papers/26288682PubMed
517,098,432Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).Bioorg Med Chem2007https://conductscience.org/library/papers/17098432PubMed
630,999,237Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).Eur J Med Chem2019https://conductscience.org/library/papers/30999237PubMed
732,462,873Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.J Med Chem2020https://conductscience.org/library/papers/32462873PubMed
822,320,327Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.J Med Chem2012https://conductscience.org/library/papers/22320327PubMed
923,562,594Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target.Bioorg Med Chem Lett2013https://conductscience.org/library/papers/23562594PubMed
1020,231,096Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.Bioorg Med Chem Lett2010https://conductscience.org/library/papers/20231096PubMed

1 to 10 of 273

See all 273 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
41,907,306Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.Pharm Sci Adv2026https://conductscience.org/library/papers/41907306

Source PubMed

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
JAK13,716PubTator's text mininghttps://conductscience.org/library/genes/3716NCBI Gene
JAK23,717PubTator's text mininghttps://conductscience.org/library/genes/3717NCBI Gene
JAK33,718PubTator's text mininghttps://conductscience.org/library/genes/3718NCBI Gene
TYK27,297PubTator's text mininghttps://conductscience.org/library/genes/7297NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40430355

GET https://conductscience.org/api/papers/v1/40430355/references?page=2

API referenceFor AI assistants